UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

Circulation research, 2021-05, Vol.128 (11), p.1728-1746

2021

Volltextzugriff (PDF)

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

European heart journal, 2016-06, Vol.37 (22), p.1720-1722

Ridker, Paul M

2016

Volltextzugriff (PDF)

How Common Is Residual Inflammatory Risk?

Circulation research, 2017-02, Vol.120 (4), p.617-619

Ridker, Paul M

2017

Volltextzugriff (PDF)

Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?

The New England journal of medicine, 2018-10, Vol.379 (16), p.1572-1574

Ridker, Paul M

2018

Volltextzugriff (PDF)

LDL cholesterol: controversies and future therapeutic directions

The Lancet (British edition), 2014-08, Vol.384 (9943), p.607-617

Ridker, Paul M, Dr Prof

2014

Volltextzugriff (PDF)

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

The New England journal of medicine, 2019-02, Vol.380 (8), p.752-762

2019

Volltextzugriff (PDF)

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

European heart journal, 2016-05, Vol.37 (17), p.1373-1379

2016

Volltextzugriff (PDF)

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

Journal of thrombosis and haemostasis, 2009-07, Vol.7, p.332-339

RIDKER, PAUL M.

2009

Volltextzugriff (PDF)

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

The New England journal of medicine, 2016-12, Vol.375 (24), p.2349-2358

2016

Volltextzugriff (PDF)

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

The Lancet (British edition), 2012-08, Vol.380 (9841), p.565-571

2012

Volltextzugriff (PDF)

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

Circulation (New York, N.Y.), 2003-01, Vol.107 (3), p.363-369

RIDKER, Paul M

2003

Volltextzugriff (PDF)

A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians

PloS one, 2015-04, Vol.10 (4), p.e0120758-e0120758

2015

Volltextzugriff (PDF)

Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease

Journal of the American College of Cardiology, 2020-05, Vol.75 (17), p.2122-2135

2020

Volltextzugriff (PDF)

Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity

Nutrition reviews, 2007-12, Vol.65 (12), p.253-259

Ridker, Paul M

2007

Volltextzugriff (PDF)

Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures

Annals of internal medicine, 2009-06, Vol.150 (11), p.795

2009

Volltextzugriff (PDF)

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

The American heart journal, 2011-10, Vol.162 (4), p.597-605

2011

Volltextzugriff (PDF)

Lipoprotein(a) and Cardiovascular Risk Prediction Among Women

Journal of the American College of Cardiology, 2018-07, Vol.72 (3), p.287-296

2018

Volltextzugriff (PDF)

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection

Circulation research, 2016-01, Vol.118 (1), p.145-156

Ridker, Paul M

2016

Volltextzugriff (PDF)

High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy

Circulation (New York, N.Y.), 2013-09, Vol.128 (11), p.1189-1197

2013

Volltextzugriff (PDF)

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2020-01, Vol.72 (1), p.31-40

2020

Volltextzugriff (PDF)

Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy

European heart journal, 2022-12, Vol.43 (46), p.4832-4844

2022

Volltextzugriff (PDF)

C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease

Clinical chemistry (Baltimore, Md.), 2009-02, Vol.55 (2), p.209-215

Ridker, Paul M

2009

Volltextzugriff (PDF)

Targeting cardiovascular inflammation: next steps in clinical translation

European heart journal, 2021-01, Vol.42 (1), p.113-131

2021

Volltextzugriff (PDF)

Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women

Circulation. Genomic and precision medicine, 2018-04, Vol.11 (4), p.e002157-e002157

2018

Volltextzugriff (PDF)

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

The New England journal of medicine, 2017-04, Vol.376 (16), p.1517-1526

2017

Volltextzugriff (PDF)

1 – 25 von 1.293

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.246)
Mit Volltextzugriff
(1.050)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.293)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(864)
Humans
(852)
Life Sciences & Biomedicine
(841)
Female
(493)
Middle Aged
(458)
Cardiovascular System & Cardiology
(440)
Risk Factors
(439)
Biological And Medical Sciences
(388)
Medical Sciences
(380)
Cardiac & Cardiovascular Systems
(373)
Male
(366)
Aged
(297)
Cardiology. Vascular System
(230)
Cardiovascular Disease
(212)
Peripheral Vascular Disease
(212)
Prospective Studies
(201)
Adult
(176)
General & Internal Medicine
(166)
Medicine, General & Internal
(166)
Inflammation
(164)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

How Common Is Residual Inflammatory Risk?

Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?

LDL cholesterol: controversies and future therapeutic directions

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians

Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease

Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity

Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Lipoprotein(a) and Cardiovascular Risk Prediction Among Women

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection

High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy

Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy

C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease

Targeting cardiovascular inflammation: next steps in clinical translation

Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

Suchergebnisse filtern